T cells

[Frontiers in Immunology] Scientists found that the proportion of CD3+TIGIT+ T cells was increased in peripheral blood and cancer tissue in colorectal cancer patients when compared with the healthy donors.

[Nature Communications] The authors demonstrated that mice living in an enriched environment were protected from carcinogen-induced liver neoplasia and transplantable syngeneic liver tumors, owning to a CD8+ T cell-dependent tumor control.

[Nature Cancer] Using a versatile platform for modulating neoantigen expression in colorectal cancer organoids and transplantation into the distal colon of mice, researchers showed that low expression precluded productive cross-priming and drove immediate T-cell dysfunction.

[Frontiers in Immunology] Sanguisorbae Radix extract (SRE) effectively inhibited the PD-1/PD-L1 interaction, thereby improving T cell receptor signaling and the NFAT-mediated luciferase activity of T cells. SRE treatment reduced tumor growth in the humanized PD-L1 MC38 cell allograft humanized PD-1 mouse model.

[Journal of the National Cancer Institute] The authors recruited 114 patients with B cell malignancies, comprising 77 acute lymphoblastic leukemia and 37 non-Hodgkin lymphoma patients, who were treated with CART19 cells.

[Leukemia] Hodgkin lymphoma patients showed a decreased CD4 T-cell fraction, a higher percentage of effector-memory T cells and higher expression of activation markers at baseline.